High Levels of Global Genome Methylation in Patients with Retinoblastoma
Overview
Affiliations
Retinoblastoma is a tumor of the embryonic neural retina in young children. The DNA methyltransferase 1 () gene has been demonstrated to be transcriptionally activated in cells lacking retinoblastoma 1 (). Thus, there is a direct interaction between and . The present study hypothesized that uncontrolled and expression may lead to a high level of global genome methylation causing a second hit or where both alleles are altered, in and/or inactivation of other genes in retinal cells. To test this, the global genome methylation levels were analyzed in 69 patients with retinoblastoma, as well as 26 healthy siblings and 18 healthy unrelated children as the control groups. Peripheral blood and tumor tissue samples were obtained from 32 patients. The expression levels of genes were also determined in cell lines. Based on the median levels of global genome methylation in patients, higher genome-wide methylation levels in peripheral blood were associated with a 3.33-fold increased risk for retinoblastoma in patients compared with all healthy controls (95% confidence interval, 0.98-11.35; P<0.0001). The level of global genome methylation and the expression of genes were increased in the WERI-RB-1 cell line, which has a mutated gene, compared with a wild-type -expressing cell line. These results supported the hypothesis that epigenetic alterations, as well as mutations in , may be associated with the oncogenesis and inheritance of retinoblastoma. The repression of genes that interact with , such as the gene family, may be important in patients with retinoblastoma with alterations in , and may serve a role in the treatment and regression of retinoblastoma.
Molecular Biological Research on the Pathogenic Mechanism of Retinoblastoma.
Ma X, Li X, Sun Q, Luan F, Feng J Curr Issues Mol Biol. 2024; 46(6):5307-5321.
PMID: 38920989 PMC: 11202574. DOI: 10.3390/cimb46060317.
RB1 gene mutations and genetic spectrum in retinoblastoma cases.
Odemis D, Kebudi R, Bayramova J, Erciyas S, Kuru Turkcan G, Tuncer S Medicine (Baltimore). 2023; 102(36):e35068.
PMID: 37682130 PMC: 10489529. DOI: 10.1097/MD.0000000000035068.
Rathore S, Verma A, Ratna R, Marwa N, Ghiya Y, Honavar S Indian J Ophthalmol. 2023; 71(7):2662-2676.
PMID: 37417104 PMC: 10491038. DOI: 10.4103/IJO.IJO_3172_22.
Katusic-Bojanac A, Plazibat M, Himelreich-Peric M, Eck-Rakovic K, Krasic J, Sincic N Int J Mol Sci. 2022; 23(16).
PMID: 36012122 PMC: 9408494. DOI: 10.3390/ijms23168861.
Karmakar A, Khan M, Kumari N, Devarajan N, Ganesan S Front Cell Dev Biol. 2022; 10:743224.
PMID: 35359459 PMC: 8960645. DOI: 10.3389/fcell.2022.743224.